56 related articles for article (PubMed ID: 213557)
1. Evidence for the involvement of cerebroside sulfate in opiate receptor binding: Studies with Azure A and jimpy mutant mice.
Law PY; Harris RA; Loh HH; Way EL
J Pharmacol Exp Ther; 1978 Nov; 207(2):458-68. PubMed ID: 213557
[TBL] [Abstract][Full Text] [Related]
2. Possible involvement of cerebroside sulfate in opiate receptor binding.
Loh HH; Law PY; Ostwald T; Cho TM; Way EL
Fed Proc; 1978 Feb; 37(2):147-52. PubMed ID: 203492
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of opiate action in neuroblastoma N18TG2 cells by lipid incorporation.
Law PY; Nicksic TD; O'Rourke MA; Koehler JE; Herz A; Loh HH
Mol Pharmacol; 1982 Mar; 21(2):492-502. PubMed ID: 6285174
[TBL] [Abstract][Full Text] [Related]
4. Naloxazone, a long-acting opiate antagonist: effects on analgesia in intact animals and on opiate receptor binding in vitro.
Pasternak GW; Childers SR; Snyder SH
J Pharmacol Exp Ther; 1980 Sep; 214(3):455-62. PubMed ID: 6105201
[TBL] [Abstract][Full Text] [Related]
5. Continuous intrathecal opioid treatment abolishes the regulatory effects of magnesium and guanine nucleotides on mu opioid receptor binding in rat spinal membranes.
Wong CS; Su YF; Watkins WD; Chang KJ
J Pharmacol Exp Ther; 1992 Jul; 262(1):317-26. PubMed ID: 1320689
[TBL] [Abstract][Full Text] [Related]
6. Effects of chronic morphine exposure on opioid inhibition of adenylyl cyclase in 7315c cell membranes: a useful model for the study of tolerance at mu opioid receptors.
Puttfarcken PS; Werling LL; Cox BM
Mol Pharmacol; 1988 May; 33(5):520-7. PubMed ID: 2835651
[TBL] [Abstract][Full Text] [Related]
7. [Characteristics of opiate receptors in the brain and spinal cord of morphine tolerant mice].
Patkina NA; Zvartau EE; Rozhanets VV; Malin KM; Kiriakov GV
Biull Eksp Biol Med; 1986 Sep; 102(9):296-8. PubMed ID: 3019449
[TBL] [Abstract][Full Text] [Related]
8. Relationship between incorporation of choline into phosphatidylcholine and morphine binding sites.
Natsuki R
Arukoru Kenkyuto Yakubutsu Ison; 1992 Feb; 27(1):57-70. PubMed ID: 1317702
[TBL] [Abstract][Full Text] [Related]
9. Decrease in delta and mu opioid receptor binding capacity in rat brain after chronic etorphine treatment.
Tao PL; Law PY; Loh HH
J Pharmacol Exp Ther; 1987 Mar; 240(3):809-16. PubMed ID: 3031275
[TBL] [Abstract][Full Text] [Related]
10. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.
McLaughlin JP; Hill KP; Jiang Q; Sebastian A; Archer S; Bidlack JM
J Pharmacol Exp Ther; 1999 Apr; 289(1):304-11. PubMed ID: 10087018
[TBL] [Abstract][Full Text] [Related]
11. Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine.
Heyman JS; Williams CL; Burks TF; Mosberg HI; Porreca F
J Pharmacol Exp Ther; 1988 Apr; 245(1):238-43. PubMed ID: 2834537
[TBL] [Abstract][Full Text] [Related]
12. The interaction of eptazocine, a novel analgesic, with opioid receptors.
Nabeshima T; Matsuno K; Kamei H; Kameyama T
Res Commun Chem Pathol Pharmacol; 1985 May; 48(2):173-81. PubMed ID: 2992058
[TBL] [Abstract][Full Text] [Related]
13. Human granulocytes contain an opiate alkaloid-selective receptor mediating inhibition of cytokine-induced activation and chemotaxis.
Makman MH; Bilfinger TV; Stefano GB
J Immunol; 1995 Feb; 154(3):1323-30. PubMed ID: 7822801
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of morphine antinociception by a CCKB antagonist in mice is mediated via opioid delta receptors.
Vanderah TW; Bernstein RN; Yamamura HI; Hruby VJ; Porreca F
J Pharmacol Exp Ther; 1996 Jul; 278(1):212-9. PubMed ID: 8764354
[TBL] [Abstract][Full Text] [Related]
15. A novel action of morphine in the rat locus coeruleus: persistent decrease in adenylate cyclase.
Beitner DB; Duman RS; Nestler EJ
Mol Pharmacol; 1989 May; 35(5):559-64. PubMed ID: 2498635
[TBL] [Abstract][Full Text] [Related]
16. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
Ward SJ; Takemori AE
J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
[TBL] [Abstract][Full Text] [Related]
17. Modification of the development of acute opiate tolerance by increased dopamine receptor sensitivity.
Martin JR; Takemori AE
J Pharmacol Exp Ther; 1987 Apr; 241(1):48-55. PubMed ID: 3572795
[TBL] [Abstract][Full Text] [Related]
18. Opiate binding in calf thalamic membranes: a selective mu 1 binding assay.
Clark JA; Houghten R; Pasternak GW
Mol Pharmacol; 1988 Sep; 34(3):308-17. PubMed ID: 2901663
[TBL] [Abstract][Full Text] [Related]
19. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic.
Raffa RB; Friderichs E; Reimann W; Shank RP; Codd EE; Vaught JL
J Pharmacol Exp Ther; 1992 Jan; 260(1):275-85. PubMed ID: 1309873
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
Zernig G; Burke T; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
